Background: A growing body of evidence indicates the importance of nutrition in cancer treatment. Ketogenic diets are one strategy that has been proposed to enhance traditional anticancer therapy. This review summarises the evidence concerning the effect of oral ketogenic diets on anthropometry, metabolism, quality of life (QoL) and tumour effects, at the same time as documenting adverse events and adherence in patients with cancer. Methods: We searched electronic databases using medical subject headings (MeSH) and text words related to ketogenic diets and cancer. Adult patients following a ketogenic diet as a complementary therapy prior, alongside or after standard anticancer treatment for more than 7 days were included. Studies were assessed for quality using the Critical Appraisal Skills Programme tools (https://www.casp-uk.net). Results: Eleven studies were included with 102 participants (age range 34-87 years) from early-phase trials, cohort studies and case reports. Studies included participants with brain, rectal or mixed cancer sites at an early or advanced disease stage. The duration of intervention ranged from 2.4 to 134.7 weeks (0.5-31 months). Evidence was inconclusive for nutritional status and adverse events. Mixed results were observed for blood parameters, tumour effects and QoL. Adherence to diet was low (50 out of 102; 49%) and ranged from 23.5% to 100%. Conclusions: High-quality evidence on the effect of ketogenic diets on anthropometry, metabolism, QoL and tumour effects is currently lacking in oncology patients. Heterogeneity between studies and low adherence to diet affects the current evidence. There is an obvious gap in the evidence, highlighting the need for controlled trials to fully evaluate the intervention.
Introduction
There is growing recognition of the impact of nutritional interventions on health outcomes (1, 2) and the supportive health-seeking behaviour of individuals with cancer (3, 4) . As part of this phenomenon, ketogenic diets (KD) have generated interest as a result of their potential to affect cancer metabolism.
Ketogenic diets are high in fat and low in carbohydrate (5) . The exact proportions of macronutrients depend on the specific type of diet (6) (7) (8) (9) . The most frequently used diet is a 4 : 1 fat to carbohydrate + protein ratio diet (5, 6) . The diet is based on complex physiological adaptations enabling an increased utilisation of fat and ketones (5) . A justification for KD is based on the observation by Warburg that most cancer cells follow an altered metabolic pathway, relying on anaerobic glycolysis, even in the presence of oxygen (10) . Also, cancer cells strategically use glycolysis for rapid cell proliferation (11) and metastases formation (12) . Data from cellular and animal studies support and extend Warburg's conclusions (13) (14) (15) (16) . Reviews concentrating on tumour-suppressive mechanisms behind the diet combine the available data from cellular, animal and clinical studies (14, (17) (18) (19) . Clinical evidence alone was reviewed in four articles. However, these reviews have a number of limitations, including unspecified inclusion criteria, combining studies of parenteral and enteral nutrition, a short duration on a KD that would not result in any potential benefits that could be attributed to ketosis, and studies that did not report or measure ketones (20) (21) (22) (23) . In addition, none of the studies assessed the quality of evidence using risk assessment tools. Currently, rigorously reviewed evidence from a dietetic perspective on oral KD is lacking.
KDs have the potential to influence many physiological processes. Patients with cancer may incur weight loss, muscle wasting and severe inflammation (24) , which can lead to morbidity and poorer quality of life (QoL) (25) . It is therefore important to determine whether KD adversely affect nutritional status in individuals with cancer.
The aim of this systematic review was to evaluate the current evidence on anthropometry, metabolic changes and systemic inflammation in individuals with cancer who were following a KD.
Materials and methods
This systematic review was registered with the International Prospective Register of Systematic Reviews (PROS-PERO) on 15 September 2017 (registration number CRD42017074011) and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (26) .
Data sources, search strategy and selection criteria
We identified relevant studies using medical subject headings (MeSH) and text words related to KD and cancer. The databases searched were: MEDLINE, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and PROSPERO. Conference abstracts were included in the search, along with ClinicalTrials.gov to identify ongoing trials. The main search strategy was created by a specialist librarian and was amended for the other databases (see Supporting information, Data S1). Identified non-English language studies were translated. Randomised and nonrandomised control trials, prospective cohort studies, retrospective cohort studies, observational and case studies with adults (>18 years) diagnosed with any type of cancer, at any stage of treatment, receiving a KD were included. A KD was defined as any dietary manipulation of fat, carbohydrate and protein aiming to achieve ketosis (5) . Studies that used KD as a complementary therapy prior, alongside or after standard anticancer treatment for longer than 7 days, were included. Studies that did not monitor ketosis during the intervention and studies with more than one intervention were excluded.
The primary outcome was a change in anthropometrics, namely body weight, the proportion of muscle mass and fat mass. Secondary outcomes were metabolic changes, including glucose level, insulin level, insulin growth factor 1 (IGF-1), cholesterol and lipid levels, Creactive protein (CRP), ketone levels, tumour size, tumour growth markers, QoL, adherence and adverse events.
The results of the literature searches were uploaded to Covidence, version 1.0 (https://www.covidence.org). Duplicates were removed. The titles and abstracts were independently screened by two researchers, and the full text of selected abstracts was obtained and screened to identify the eligible publications (see PRISMA flow chart 26 ).
Quality appraisal
Studies were assessed for quality using the Critical Appraisal Skills Programme tools for cohort studies (CASP) (27) (see Supporting information, Data S2).
Data synthesis
No studies were suitable for pooling the results and so a narrative analysis is presented.
Results
In total, 2367 titles were identified. In addition, 15 studies were found through manual searching. After the removal of 130 duplicates, 2252 abstracts were screened and 2217 studies were then excluded. Subsequently, 35 full texts were assessed for eligibility. From those, 24 were excluded (see Supporting information, Data S3). Eleven studies were included (see PRISMA flow chart, Fig. 1 ).
Synthesis

Study characteristics
We included three early-phase single-arm clinical trials (28) (29) (30) , three prospective cohort studies (31) (32) (33) , one retrospective review (34) and four case reports (6, (35) (36) (37) . Only two studies were designed to compare intervention and control groups: one retrospective review (34) and one prospective study (33) . In total, 102 participants followed KD and their age ranged between 34 and 87 years. Mean (SD) baseline body mass index (BMI) ranged from 23.5 (6) kg m -2 to 29.46 (5) kg m -2 . Participants in eight studies had an advanced cancer stage (30) (31) (32) (33) (34) (35) 37) . In three studies, the cancer stage ranged from an early to a more advanced stage (6, 28, 36) . Five studies involved participants with brain cancer (30, (33) (34) (35) 37) , one study involved rectal cancer (6) and five studies had participants with mixed cancer sites (28, 29, 31, 32, 36) . The duration of intervention ranged from 2.4 to 134.7 weeks. KD was used as a sole therapy or in combination with standard therapies and this differed not only between studies, but also within studies (Table 1 ).
Study quality
Quality of evidence was very low. The cohort studies had limited information on eligibility of participants, and details of recruitment were only reported in two studies (29, 30) . Exposure to KD was only accurately measured in one study (32) , which monitored ketosis, energy and nutrient intake. Outcomes were accurately measured in three studies (28, 31, 32) . All studies identified the main confounding factors; however, no study adjusted for them. Follow-up was sufficiently long in all of the studies. Studies lacked precision and reliability, having a small sample size, insufficient statistical analysis, and multiple limitations in the design, methodology and outcomes reported.
Intervention
All studies investigated the effect of oral KD; however, there was considerable variation in how the diet was delivered. Three studies followed a traditional KD with a 4 : 1 or 3 : 1 fat (F) to carbohydrate CHO) + protein (P) kg m -2 (F : CHO + P) (28, 33, 37) , two studies used a ratio of F : CHO + P between 0.7 : 1 and 1.8 : 1 (32, 36) , three (29, 34, 35) , two studies used a low glycaemic index diet (<70 g day À1 CHO) (30, 31) and one study used a Paleolithic KD with a F : P ratio of 2 : 1 (6) . All studies encouraged participants to eat to satiety; however, only two studies reported on energy and macronutrient intake (32, 36) . Four studies involved a dietitian or nutritionist (28, 33, 36, 37) and seven studies applied some form of dietary monitoring that included a tailored dietary regimen with provided meals (28) , food diaries (36) , dietary recall (32) , diet software (34) , telephone calls (37) or telephone calls and in-person visits (6, 31) . The adherence was assessed by study completion and measuring the level of ketosis. Urine ketosis was measured with or without blood analysis taken daily, weekly, biweekly or at set time points (see Supporting information, Data S4).
Primary and secondary outcomes
Anthropometry Nine studies measured body weight and reported a mean weight loss of 1.86-13 kg. Weight was measured between 2.4 and 97.8 weeks (22.5 months). Fine et al. (32) monitored energy intake, observing a 4% mean decrease in weight but a mean energy deficit of 35%. Klement and Sweeney (36) also monitored energy intake and observed significant weight loss albeit in patients on a hypocaloric diet intending to lose weight. Champ et al. (34) reported similar findings. Five studies (6, (28) (29) (30) (31) 35) reported a significant reduction in weight but did not report on energy intake. One study did not observe a significant weight loss (35) . Five studies reported a decrease in BMI (6, 29, 31, 35, 37) consistent with weight loss. Body composition was measured by one study (36) , observing a decrease in fat mass and an increase in muscle mass relative to body weight (Table 2) .
Biochemical parameters
Blood glucose
Ten studies assessed blood glucose at baseline and follow-up. Four studies reported a decrease in blood glucose (6, 31, 32, 34) , five reported no significant changes (28) (29) (30) 35, 36) and one study showed problems with maintenance of glucose below 80 mg dL À1 (37) . Two studies reported on correlation between b-hydroxylbutyrateand glucose concentration. One study found significant negative correlation (P = 0.05) (36) , whereas another reported no significant change (29) .
Lipid profile
Seven studies reported on changes in blood lipids. Four studies did not observe any significant changes in triglycerides, cholesterol, high-density lipoprotein and low-density lipoprotein (29, 30, 35, 36) . One study reported a significant drop in low-density lipoprotein and high-density lipoprotein (31) . One study observed elevated lipid enzymes, with stable triglycerides (6) and two studies reported an elevated cholesterol and low-density lipoprotein (6, 37) .
Other parameters
Studies reported on kidney (6, 29, 32) , liver (6, 29, 31, 36) and thyroid function (6, 36) with no changes in measured markers. Also, there were no differences in inflammatory markers in two studies (32, 36) , whereas one study reported a decrease in CRP (6) . A negative correlation between bhydroxylbutyrate and insulin but not IGF-1 and IGF-2 was reported in one study (32) . The decrease in insulin 75% to 90% was observed in participants who achieved a 10-to 35-fold increase (P = 0.018) in ketosis (32) ; however, no changes were reported in another study (36) . In participants with diabetes, one reported a 75% decrease in insulin taken compared to baseline (31) and one stopped insulin doses completely (29) . One study reported a significant increase (P < 0.05) in the level of the plasma protein carbonyl (biomarker of oxidative stress) compared to baseline (28) . Details on all biochemical parameters are provided in Table 2 .
Tumour effects
All eleven studies reported on tumour stability and progression; however, the diagnostic tool used was only reported in eight studies; four used magnetic resonance imaging (6, 30, 33, 37) , three used positron emission tomography (29, 32, 37) and one used computed tomography scans (29) . As a result of low compliance, most of the studies could not perform any probability statistical analysis on effect size. One study compared the results between participants who were adherent or not adherent to the diet (32) . Patients with three-fold higher ketosis had stable disease or partial remission compared to those with progressive diseases (P = 0.018) (32) . One study reported a 50% reduction in seizure frequency after a 13.2-month follow-up (35) . Some studies reported outstanding results in some patients, whereas, in others, the disease progressed (Table 2) . Survival Zahra et al. (28) showed no difference in survival between patients who adhered to a diet and those who stopped after 22 months. Champ et al. (34) reported that four patients were alive, three with recurrence after 14 months of follow-up, one patient without recurrence for 12 months, and two patients died after 6.3 months and ALT, alanine aminotransferase; AST, aspartate aminotransferase; BHB, b-hydroxybutyrate; CRP, C-reactive protein; FM, fat mass; FFM, fat-free mass; HDL, high-density lipoprotein; HbA1, haemoglobin A1; IGF 1/2, insulin-like growth factor 1/2; LDL, low-density lipoprotein; NR, not reported; NSD, no significant difference; sig, significant; TG, triglycerides.
20 months. Rieger et al. (30) showed that patient survival from the time of the diet was 32 weeks (range 6-86 weeks) and also compared survival with patients treated with standard therapy; however, the results showed no difference. Furthermore, the study showed a trend in longer progression-free survival in patients with stable ketosis (P = 0.069). In the study by Tan-Shalaby et al. (29) , from the four patients who completed the intervention, survival ranged from 40 to 131 months from the start of the diet (29) . In the study by Klement and Sweeney (36) , five patients with an early cancer were alive at 4-month follow-up and one patient with metastatic cancer died 11 months from diagnosis. Only one study compared reported and expected survival (35) , indicating a survival of 13 months versus an expected 7.8 months in one patient and a survival of 17 months compared to an expected 7.4 months in another.
Adherence From 102 patients who started a KD intervention, 50 (49%) were able to complete the diet.
Ketosis
All studies reported ketosis; however, not all patients were able to maintain ketosis. Ketosis was relatively low and ranged between 0.03 and 15 mmol L À1 (Table 2 ). Only TanShalaby et al. (29) investigated whether patients achieved the glucose ketone index (29) that has been proposed to monitor the efficacy of metabolic therapy (38) ; however, patients did not achieved values predicted for therapeutic effects (<1.0) (see Supporting information, Data S4).
Adverse events
In total, adverse events were reported in 50 patients. Eight studies measured adverse events (28) (29) (30) (31) (32) 34, 36, 37) and four used a validated tool (28, 32, 34, 36) . Most studies reported fatigue, constipation, diarrhoea, hyperuricaemia and vomiting. From 50 patients, 16 reported fatigue, 12 reported constipation, eight reported diarrhoea, eight reported hyperuricaemia and four reported vomiting. One study reported hunger in two and craving for sugar in five out of 12 patients (30) . Hyperkalaemia and hypokalaemia were reported in two patients. Also, two patients experienced leucocytopaenia. Adverse events such as oesophagitis, anaemia, hypomagnesaemia, pedal oedema, halitosis, hypoglycaemia, hyperlipidaemia and deep vein thrombosis were observed only once across studies.
Quality of life
Three studies assessed the QoL with validated European Organization for Research and Treatment core QoL questionnaire (29, 31, 36) . No consistent results were reported.
Discussion
From hypothetical conjecture based on academic modelling supported by animal and cellular studies, there are sound theoretical bases for KDs suppressing tumour growth (10, 19, 20) . However, strong conclusive evidence in clinical practice is still lacking.
The current studies demonstrated that patients on a KD lose weight. This is of concern for sarcopenic and malnourished patients because body composition and nutritional status have been shown to influence clinical outcomes (24, 39) . However, most of the studies did not monitor energy intake and it is very likely patients followed a hypocaloric diet. This was demonstrated in two studies (31, 36) and is possibly attributed to a selfadministrated diet and limited diet monitoring. Also, it is widely accepted that body weight is a weak predictor of changes in health status (40) because patients might lose fat but not muscle mass (36) . Hence, further studies of KD that control energy and macronutrient intake and measure body composition are required.
This review found a low adherence to KD as a result of a number of possible factors. The proportion of macronutrients influence ketosis. Studies followed a variable F : CHO + P ratio and thus the ketosis may have been affected by levels of carbohydrate and protein. It was originally proposed that carbohydrate should be maintained below 20 g day -1 , although no data exist to define what level of carbohydrate represents a threshold for maintenance of ketosis (19) . Studies in this review used a great variation of carbohydrate, reaching 70 g day -1 .
Also, it has been suggested that a very high protein intake may counteract the level of ketosis by providing glucogenic amino acids for production of glucose when the level of protein exceeds the normal nonstarvation protein turnover (19) . Hence, the carbohydrate and protein ratio may explain a low ketosis.
Furthermore, the maintenance of ketosis and adherence to a KD are very likely underpinned by limitations in the delivery of the diet and monitoring. Schwartz et al. (37) suggested that patients require weekly contact with a dietitian. However, most of the studies tested self-administrated diet and had little control over the food selection, energy and nutritional composition. By contrast, Zahra et al. (28) provided tailored meals but the compliance was still poor, indicating that delivery of the diet represents only one contributor to adherence. It was concluded that patients found a 4 : 1 fat to carbohydrate ratio to be unpalatable (28) . Possibly, palatability plays a crucial role and patients are unlikely to follow a restricted diet for a prolonged period of time. There were no obvious differences in adherence between studies with the original 4 : 1 KD and those using a modified Atkins diet or similar macronutrient ratio. The evidence indicates that following the diet is difficult for patients, especially incorporating the diet into family life (31) . Schmidt et al. (31) suggested that patient's motivation is critical and that diet would only be a good option in highly motivated patients. Furthermore, adherence is closely related to adverse events. It is difficult to differentiate between events related to treatment and those specific to the diet, especially in very advanced cancer. Constipation, diarrhoea and fatigue were the most frequently reported problems. As a result of a low dietary fibre content, patients following a KD are likely to experience constipation. Studies that reported on dietary fibre showed a range between 7.9 and 12.5 g day À1 , whereas 20-30 g day À1 is recommended (41) . On the other hand, if a substantial proportion of fat in a diet is not introduced gradually, it might lead to diarrhoea (42) . Also, a decrease in carbohydrate intake and simulation of fasting may lead to fatigue. These adverse events were more frequent in the first 4 weeks on a diet, indicating that time for adaptation is required (31) . Concerns about acidosis, kidney and hepatic functional impairment have not been confirmed. Two studies reported hyperuricaemia, which needs further investigation. Many adverse events were reported as single cases, indicating the importance of considering comorbidities when prescribing the diet (34) . Mixed results were observed in blood parameters, tumour, QoL and survival. No clear trend in changes in glucose and lipids could be concluded. An inverse correlation between glucose and ketones level was demonstrated only in two studies (32, 36) . Tumour responses were better in patients with early stage of disease (31, 36) or with low-grade tumours when the ketogenic diet was used as a sole therapy (33) . Patients with stable disease or partial remission were able to achieve three-fold higher ketosis than patients with more progressive disease (32) . Some patients achieved outstanding results on tumour stability and survival, whereas others progressed. Most of the studies included mixed cancer populations and thus it is unclear what cancer site could benefit from the diet the most. However, positive responses were clearly observed in patients with brain tumours. The QoL parameters slightly improved, worsened or remained unchanged. However, conclusions are difficult to ascertain from the available data because of a high level of bias, a small number of patients who had a high level of adherence to the diet and the lack of a control group.
Conclusions
The current studies represent preliminary evidence and show that the KD is potentially feasible and does not cause life-threatening events in patients with cancer. However, adherence is low and possibly linked to a limitation in diet delivery, as well as a lack of monitoring and follow-up. A high level of heterogeneity among studies prevents the formulation of conclusions. To develop the evidence base for the use of KD in clinical practice, highquality control trials are required.
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